Literature DB >> 28815831

Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database.

Neeraja Konuthula1, Alfred M Iloreta1, Brett Miles1, Ryan Rhome2, Umut Ozbek3, Eric M Genden1, Marshall Posner4, Krzysztof Misiukiewicz4, Satish Govindaraj1, Raj Shrivastava5, Vishal Gupta2, Richard L Bakst2.   

Abstract

BACKGROUND: Given the rarity of esthesioneuroblastoma, it is difficult to validate a staging system. The purpose of this study was to investigate the utility of the Kadish staging system in esthesioneuroblastoma using the National Cancer Database (NCDB).
METHODS: One thousand one hundred sixty-seven patients with esthesioneuroblastoma were identified from the NCDB.
RESULTS: Five-year survival was 80.0% for Kadish A, 87.7% for Kadish B, 77.0% for Kadish C, and 49.5% for Kadish D. Kadish B had higher survival than Kadish A. More Kadish B patients received surgery with adjuvant therapy than Kadish A patients (41.6% vs 32.5%; P = .0038) and also had more positive margins (21.6% vs 11.3%; P = .03). There was no difference in age distribution, sex, race, or neck dissection status between the 2 groups.
CONCLUSION: Kadish B had greater survival than Kadish A, but the treatment characteristics could not account for this difference. The utility of early-stage Kadish staging is uncertain and requires further study.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  esthesioneuroblastoma; head and neck cancer; oncology; outcomes; statistics

Mesh:

Year:  2017        PMID: 28815831      PMCID: PMC5993196          DOI: 10.1002/hed.24770

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  16 in total

1.  Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center.

Authors:  J R Austin; H Cebrun; M M Kershisnik; A K El-Naggar; A S Garden; F Demonte; L E Ginsberg; S M Lippman; H Goepfert
Journal:  Skull Base Surg       Date:  1996

2.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

3.  Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol.

Authors:  Joanne Rimmer; Valerie J Lund; Timothy Beale; William I Wei; David Howard
Journal:  Laryngoscope       Date:  2014-02-04       Impact factor: 3.325

Review 4.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

5.  Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.

Authors:  Eduardo M Diaz; Richard H Johnigan; Colin Pero; Adel K El-Naggar; Dianna B Roberts; James L Barker; Franco DeMonte
Journal:  Head Neck       Date:  2005-02       Impact factor: 3.147

6.  Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.

Authors:  Mahmut Ozsahin; Guenther Gruber; Olimpia Olszyk; Omur Karakoyun-Celik; Berrin Pehlivan; David Azria; Martine Roelandts; Johannes H A M Kaanders; Mustafa Cengiz; Marco Krengli; Oscar Matzinger; Abderrahim Zouhair
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

7.  Olfactory neuroblastoma: past, present, and future?

Authors:  Valerie J Lund; David Howard; William Wei; Margaret Spittle
Journal:  Laryngoscope       Date:  2003-03       Impact factor: 3.325

8.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

9.  Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.

Authors:  Gabriel G Malouf; Odile Casiraghi; Eric Deutsch; Joel Guigay; Stéphane Temam; Jean Bourhis
Journal:  Eur J Cancer       Date:  2013-01-10       Impact factor: 9.162

10.  Combined modality therapy of esthesioneuroblastoma.

Authors:  J Nicolas McLean; Sunjay R Nunley; Carmen Klass; Charles Moore; Susan Müller; Peter A S Johnstone
Journal:  Otolaryngol Head Neck Surg       Date:  2007-06       Impact factor: 3.497

View more
  5 in total

1.  Esthesioneuroblastoma presenting with orbital signs and ectopic adrenocorticotropic hormone syndrome.

Authors:  Wesley M Gillette; Donald Carroll Hubbard; Jana Nicole Waters; Adam Stephen Johnson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-11-15

2.  Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution's Clinical Experience.

Authors:  Jakob Liermann; Mustafa Syed; Thomas Held; Denise Bernhardt; Peter Plinkert; Christine Jungk; Andreas Unterberg; Stefan Rieken; Jürgen Debus; Klaus Herfarth; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2018-11-20       Impact factor: 6.639

3.  Management of orbital invasion in esthesioneuroblastoma: 14 years' experience.

Authors:  Ruichen Li; Shu Tian; Yi Zhu; Li Yan; Wenjia Zhu; Huatao Quan; Shengzi Wang
Journal:  Radiat Oncol       Date:  2019-06-13       Impact factor: 3.481

4.  The role of chemotherapy in the management of olfactory neuroblastoma: A 40-year surveillance, epidemiology, and end results registry study.

Authors:  Ryan J Brisson; Thomas J Quinn; Rohan L Deraniyagala
Journal:  Health Sci Rep       Date:  2021-05-02

5.  Short-Term Morbidity and Predictors of Adverse Events Following Esthesioneuroblastoma Surgery.

Authors:  Khodayar Goshtasbi; Jack L Birkenbeuel; Mehdi Abouzari; Brandon M Lehrich; Tyler M Yasaka; Arash Abiri; Ethan G Muhonen; Frank P K Hsu; Edward C Kuan
Journal:  Am J Rhinol Allergy       Date:  2020-10-29       Impact factor: 2.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.